KR20220041154A - 상처 치유를 위한 yap 억제 - Google Patents

상처 치유를 위한 yap 억제 Download PDF

Info

Publication number
KR20220041154A
KR20220041154A KR1020227006337A KR20227006337A KR20220041154A KR 20220041154 A KR20220041154 A KR 20220041154A KR 1020227006337 A KR1020227006337 A KR 1020227006337A KR 20227006337 A KR20227006337 A KR 20227006337A KR 20220041154 A KR20220041154 A KR 20220041154A
Authority
KR
South Korea
Prior art keywords
wound
enf
days
skin
yap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227006337A
Other languages
English (en)
Korean (ko)
Inventor
샤믹 마샤락
헤더 엘리자베스 데자르뎅-파크
미미 보렐리아
마이클 프란시스 데이빗
마이클 티. 론게이커
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20220041154A publication Critical patent/KR20220041154A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227006337A 2019-07-26 2020-07-24 상처 치유를 위한 yap 억제 Ceased KR20220041154A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962879369P 2019-07-26 2019-07-26
US62/879,369 2019-07-26
PCT/US2020/043420 WO2021021607A2 (en) 2019-07-26 2020-07-24 Yap inhibition for wound healing

Publications (1)

Publication Number Publication Date
KR20220041154A true KR20220041154A (ko) 2022-03-31

Family

ID=74229013

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227006337A Ceased KR20220041154A (ko) 2019-07-26 2020-07-24 상처 치유를 위한 yap 억제

Country Status (10)

Country Link
US (1) US20220313658A1 (cg-RX-API-DMAC7.html)
EP (1) EP4003334A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022541572A (cg-RX-API-DMAC7.html)
KR (1) KR20220041154A (cg-RX-API-DMAC7.html)
CN (1) CN114401718A (cg-RX-API-DMAC7.html)
AU (1) AU2020320171B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001196A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144185A1 (cg-RX-API-DMAC7.html)
IL (1) IL289923A (cg-RX-API-DMAC7.html)
WO (1) WO2021021607A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102550631B1 (ko) * 2021-03-16 2023-07-03 (주)파인헬스케어 인공지능을 이용한 욕창 단계 평가 및 치료 추천을 제공하는 장치 및 방법
CA3220398A1 (en) * 2021-07-30 2023-02-02 Geoffrey Gurtner Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
US20240366565A1 (en) * 2021-09-09 2024-11-07 The Board Of Trustees Of The Leland Stanford Junior University Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
CN114288474A (zh) * 2021-12-27 2022-04-08 湖北中部医疗科技有限公司 一种促毛囊再生用真皮层、人工皮肤及其制备方法
EP4514393A4 (en) * 2022-04-28 2026-04-01 Univ Leland Stanford Junior PIEZO-ELECTRIC INHIBITION FOR Wound Healing
CN116694089B (zh) * 2022-09-19 2024-03-26 广州贝奥吉因生物科技股份有限公司 一种用于抑制瘢痕的水凝胶及其制备方法和应用
CN116602265B (zh) * 2023-05-25 2024-05-14 北京工业大学 一种用于建立瘢痕疙瘩动物模型的智能控制系统及方法
CN117679393A (zh) * 2023-12-04 2024-03-12 中山大学附属第一医院 一种负载维替泊芬治疗增生性瘢痕的生物粘性纳米缓释颗粒
US20260115352A1 (en) 2024-10-28 2026-04-30 Cilag Gmbh International Verteporfin Containing Silicone Topical Skin Adhesive for Wound Closure and Reduced Scarring

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060140984A1 (en) * 2002-10-25 2006-06-29 Foamix Ltd. Cosmetic and pharmaceutical foam
GB0823265D0 (en) * 2008-12-20 2009-01-28 Convatec Technologies Inc Antimicrobial Composition
DE102010009572A1 (de) * 2010-02-26 2011-09-01 Euroderm Gmbh Verfahren zum Begünstigen der Heilung von Hautwunden unter Verwendung der Zellen der Haarwurzelscheide, Präparat und Herstellverfahren
JP2014500275A (ja) * 2010-12-06 2014-01-09 フォリカ,インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US9655967B2 (en) * 2011-12-09 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of focal adhesion kinase for control of scar tissue formation
KR101385196B1 (ko) * 2012-05-17 2014-04-14 주식회사 유니크메디케어 광 조사를 이용한 광감각제―펩타이드를 유효성분으로 포함하는 발모 개선 또는 촉진용 조성물 및 이를 이용한 방법
US20150157584A1 (en) * 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
EP2897689A4 (en) * 2012-09-24 2016-03-30 Cormatrix Cardiovascular Inc COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
IL248468A0 (en) * 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing

Also Published As

Publication number Publication date
AU2020320171B2 (en) 2025-05-29
IL289923A (en) 2022-03-01
BR112022001196A2 (pt) 2022-03-15
US20220313658A1 (en) 2022-10-06
EP4003334A2 (en) 2022-06-01
CA3144185A1 (en) 2021-02-04
CN114401718A (zh) 2022-04-26
AU2020320171A1 (en) 2022-02-17
WO2021021607A3 (en) 2021-04-08
EP4003334A4 (en) 2023-08-16
WO2021021607A2 (en) 2021-02-04
JP2022541572A (ja) 2022-09-26

Similar Documents

Publication Publication Date Title
AU2020320171B2 (en) YAP inhibition for wound healing
CN102625853B (zh) 表皮分化微小rna标记及其应用
US20230210928A1 (en) Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent
JP6836950B2 (ja) 細胞外マトリックスに関連した皮膚色素斑の分子シグネチャー
Bellei et al. Regenerative medicine-based treatment for vitiligo: an overview
Zcharia et al. Heparanase regulates murine hair growth
JP6223960B2 (ja) 細胞外マトリックスの組織化に関連した皮膚色素斑の分子シグネチャー
Gong et al. Protective mechanism of adipose-derived stem cells in remodelling of the skin stem cell niche during photoaging
TWI614031B (zh) 防止皮膚老化相關症狀的醫藥組合物及其使用方法
Chakraborty et al. Stem-cell therapy in dermatology–Challenges and opportunities
US20250321225A1 (en) Skin damage organoid model and drug screening method using the same
US20250195474A1 (en) Piezo Inhibition for Wound Healing
HK40071204A (en) Yap inhibition for wound healing
Bai et al. ACE2 Inhibits Dermal Regeneration Through Ang II in Tissue Expansion
Mohammed et al. Biological skin regeneration using epigenetic targets
WO2023215294A1 (en) Complement pathway inhibition for wound healing
US20230355498A1 (en) Hair growth agent
WO2024248945A2 (en) Axl signaling pathway activator for wound healing
Al Shueili The Roles of ING5 in Regeneration and Maintaining Genomic Stability (in vivo model)
US20230390356A1 (en) Hair growth agent
An Uncovering the Cellular and Molecular Mechanisms of UVB-Induced Melanocyte Stem Cell Activation and Epidermal Migration
Nicu et al. 922 Dermal white adipose tissue secretes hepatocyte growth factor to promote human hair follicle growth and pigmentation
Syu et al. 920 The non-coding control region of Trichodysplasia spinulosa polyomavirus is responsible for cell-type specific viral gene expression in vivo
Hopkins et al. 919 Overexpression of cyclooxygenase-2 in the skin of adult transgenic mice leads to sebaceous gland hyperplasia and thinning of hair shafts
Sallee et al. 923 Molecular phenotyping of lichen planopilaris revealed dysregulation of cholesterol/fatty acid metabolism, fibrosis and mast cell pathways

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601